Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 3810944 in Solid Tumours and Melanoma
NCT07224425Phase 1Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2026
- Primary completion
- Oct 2029
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of BI 3810944 in solid tumor and melanoma (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Occurrence of Cytokine Release Syndrome Grade 1 or 2 at 2 months, Occurrence of Dose Limiting Toxicities at 2 months and 1 more. Started Feb 2026; status: recruiting.
02
Drugs
BI 3810944
03
Conditions
solid tumormelanoma
Beyond the preview
Go deeper on NCT07224425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07224425.